Cargando…
Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation
BACKGROUND: Long-standing atrial fibrillation is associated with atrial functional mitral regurgitation (AFMR) with atriogenic tethering. We compared the outcomes of patch augmentation (PA) and valve replacement (VR) for AFMR. METHODS: We retrospectively compared the data of 16 patients who underwen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641335/ https://www.ncbi.nlm.nih.gov/pubmed/36389294 http://dx.doi.org/10.21037/jtd-22-828 |
_version_ | 1784826077612343296 |
---|---|
author | Morisaki, Akimasa Takahashi, Yosuke Fujii, Hiromichi Sakon, Yoshito Murakami, Takashi Shibata, Toshihiko |
author_facet | Morisaki, Akimasa Takahashi, Yosuke Fujii, Hiromichi Sakon, Yoshito Murakami, Takashi Shibata, Toshihiko |
author_sort | Morisaki, Akimasa |
collection | PubMed |
description | BACKGROUND: Long-standing atrial fibrillation is associated with atrial functional mitral regurgitation (AFMR) with atriogenic tethering. We compared the outcomes of patch augmentation (PA) and valve replacement (VR) for AFMR. METHODS: We retrospectively compared the data of 16 patients who underwent PA for AFMR with the data of 15 patients who underwent VR between 2008 and 2021. Patients with a left ventricular ejection fraction (LVEF) of <50% were excluded. We also performed atrial plication and left appendage closure if the patients had no weak atrial wall that led to severe bleeding. RESULTS: The median age was 72.5 and 76.0 years in the PA and VR groups, respectively. The PA group had a longer cardiopulmonary bypass time (206 vs. 172 min, P=0.012). Although there were no differences in hospital morbidity and mortality between the PA and VR groups, one patient underwent reoperation for patch perforation in the PA group. The overall 3-year survival rate was 93.8% and 100% in the PA and VR groups, respectively (P=0.878). The 3-year rate of freedom from major adverse cardiac events was 75.0% and 53.6% in the PA and VR groups, respectively (P=0.181). Three and six patients were readmitted for congestive heart failure in the PA and VR groups, respectively. Two patients in the PA group developed severe recurrent regurgitation, including one patient who required reoperation. No patients in the VR group required reoperation. The postoperative left atrial volume index (LAVI) was associated with thromboembolic events (P=0.016). CONCLUSIONS: PA may achieve comparable outcomes to those of VR for AFMR. Operative procedures should be chosen based on each patient’s background. Atrial reduction could be considered to prevent thromboembolic events. |
format | Online Article Text |
id | pubmed-9641335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-96413352022-11-15 Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation Morisaki, Akimasa Takahashi, Yosuke Fujii, Hiromichi Sakon, Yoshito Murakami, Takashi Shibata, Toshihiko J Thorac Dis Original Article BACKGROUND: Long-standing atrial fibrillation is associated with atrial functional mitral regurgitation (AFMR) with atriogenic tethering. We compared the outcomes of patch augmentation (PA) and valve replacement (VR) for AFMR. METHODS: We retrospectively compared the data of 16 patients who underwent PA for AFMR with the data of 15 patients who underwent VR between 2008 and 2021. Patients with a left ventricular ejection fraction (LVEF) of <50% were excluded. We also performed atrial plication and left appendage closure if the patients had no weak atrial wall that led to severe bleeding. RESULTS: The median age was 72.5 and 76.0 years in the PA and VR groups, respectively. The PA group had a longer cardiopulmonary bypass time (206 vs. 172 min, P=0.012). Although there were no differences in hospital morbidity and mortality between the PA and VR groups, one patient underwent reoperation for patch perforation in the PA group. The overall 3-year survival rate was 93.8% and 100% in the PA and VR groups, respectively (P=0.878). The 3-year rate of freedom from major adverse cardiac events was 75.0% and 53.6% in the PA and VR groups, respectively (P=0.181). Three and six patients were readmitted for congestive heart failure in the PA and VR groups, respectively. Two patients in the PA group developed severe recurrent regurgitation, including one patient who required reoperation. No patients in the VR group required reoperation. The postoperative left atrial volume index (LAVI) was associated with thromboembolic events (P=0.016). CONCLUSIONS: PA may achieve comparable outcomes to those of VR for AFMR. Operative procedures should be chosen based on each patient’s background. Atrial reduction could be considered to prevent thromboembolic events. AME Publishing Company 2022-10 /pmc/articles/PMC9641335/ /pubmed/36389294 http://dx.doi.org/10.21037/jtd-22-828 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Morisaki, Akimasa Takahashi, Yosuke Fujii, Hiromichi Sakon, Yoshito Murakami, Takashi Shibata, Toshihiko Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
title | Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
title_full | Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
title_fullStr | Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
title_full_unstemmed | Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
title_short | Patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
title_sort | patch augmentation vs. valve replacement for patients with atrial functional mitral regurgitation and long-standing atrial fibrillation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641335/ https://www.ncbi.nlm.nih.gov/pubmed/36389294 http://dx.doi.org/10.21037/jtd-22-828 |
work_keys_str_mv | AT morisakiakimasa patchaugmentationvsvalvereplacementforpatientswithatrialfunctionalmitralregurgitationandlongstandingatrialfibrillation AT takahashiyosuke patchaugmentationvsvalvereplacementforpatientswithatrialfunctionalmitralregurgitationandlongstandingatrialfibrillation AT fujiihiromichi patchaugmentationvsvalvereplacementforpatientswithatrialfunctionalmitralregurgitationandlongstandingatrialfibrillation AT sakonyoshito patchaugmentationvsvalvereplacementforpatientswithatrialfunctionalmitralregurgitationandlongstandingatrialfibrillation AT murakamitakashi patchaugmentationvsvalvereplacementforpatientswithatrialfunctionalmitralregurgitationandlongstandingatrialfibrillation AT shibatatoshihiko patchaugmentationvsvalvereplacementforpatientswithatrialfunctionalmitralregurgitationandlongstandingatrialfibrillation |